A CASE OF SEVERE ASTHMA RESPONSIVE TO OMALIZUMAB TREATMENT DESPITE A LOW SERUM IGE LEVEL AND LACK OF SENSITIZED ALLERGENS
-
- Sugino Yasuteru
- Department of Respiratory Medicine, Toyota Memorial Hospital
-
- Sanda Ryo
- Department of Respiratory Medicine, Toyota Memorial Hospital
-
- Takagi Yasuyuki
- Department of Respiratory Medicine, Toyota Memorial Hospital
-
- Kato Motoaki
- Department of Respiratory Medicine, Toyota Memorial Hospital
-
- Ohta Akiko
- Department of Respiratory Medicine, Toyota Memorial Hospital
-
- Okumura Junya
- Department of Respiratory Medicine, Toyota Memorial Hospital
-
- Nagai Hideaki
- Department of Dermatology, Toyota Memorial Hospital
Bibliographic Information
- Other Title
-
- 血清IgE低値でアレルゲンが明瞭でない重症喘息にオマリズマブが奏効した1例
- 症例報告 血清IgE低値でアレルゲンが明瞭でない重症喘息にオマリズマブが奏効した1例
- ショウレイ ホウコク ケッセイ IgE テイチ デ アレルゲン ガ メイリョウ デ ナイ ジュウショウ ゼンソク ニ オマリズマブ ガ ソウコウ シタ 1レイ
Search this article
Abstract
A 49-year-old female patient suffering from severe intractable asthma uncontrolled even with high-dose inhaled glucocorticosteroids (fluticasone 1000μg/day+ciclesonide 800μg/day), salmeterol inhaler (100μg/day) and oral betamethasone (1mg/day) was admitted to our hospital because of severe asthma attack. The total serum IgE level was low at 9 (IU/mL). Though perennial allergens was also negative, administration of 150mg omalizumab was started in August 2009 with the patient's consent, resulting in noticeable improvements in asthma symptoms and the peak expiratory flow (PEF) were achieved. Due to her weight gain and general malaise, the drug was discontinued after the second administration, resulting in worsening of asthma symptoms. Omalizumab therapy was restarted in January 2010 and marked improvements in asthma symptoms and PEF were noted. The effects continued for approximately three weeks after administration. After the sixth administration, the dose of oral betamethasone successfully reduced to 0.5mg/day. When comparing the six-month preand post-omalizumab therapy period, asthma-related events such as unscheduled hospital visits were also reduced, and the dose of oral betamethasone could also be reduced to 64% of the pretherapy period after the omalizumab treatment. This case strongly suggests the therapeutic effect of omalizumab in the treatment of severe intractable asthma with low serum IgE level without identifiable allergens.
Journal
-
- Japanese Journal of Allergology
-
Japanese Journal of Allergology 59 (11), 1572-1579, 2010
Japanese Society of Allergology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679967026560
-
- NII Article ID
- 110007989019
-
- NII Book ID
- AN00012583
-
- ISSN
- 13477935
- 00214884
-
- NDL BIB ID
- 10925793
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- CiNii Articles
-
- Abstract License Flag
- Disallowed